CJC-1295 Side Effects: Common, Serious, and Long-Term Risks

CJC-1295 is a synthetic growth-hormone-releasing hormone analog. Reported side effects include injection-site redness, flushing, headache, dizziness, water retention, tingling, and mild nausea. Because it raises growth hormone and IGF-1, longer exposure may increase risks such as joint pain, insulin resistance, and fluid retention. CJC-1295 is not FDA-approved [1][2][3].

Quick facts: CJC-1295 side effects at a glance

CJC-1295 side effects can be mild, serious, or unknown because long-term human safety data are limited. The most important safety point is that CJC-1295 is not FDA-approved, and FDA has identified CJC-1295 as a bulk drug substance that raises significant safety concerns for 503A compounding [3].

• Most discussed short-term effects: injection-site redness, itching, swelling, flushing, headache, dizziness, nausea, tingling, and water retention [1][4][8].
• GH and IGF-1-related risks: joint pain, swelling, carpal-tunnel-like symptoms, insulin resistance, and acromegaly-like changes if growth hormone activity is excessive [5][6][8].
• Cancer caution: IGF-1 is involved in cell growth signaling, so people with active malignancy, recent cancer, or unexplained masses need physician evaluation [7][8].
• Regulatory issue: compounded drugs are not FDA-approved, and CJC-1295 has additional FDA safety concerns beyond the general limits of compounding [3][9].

What is CJC-1295 and how does it work in the body?

CJC-1295 (modified GRF 1-29) is a synthetic growth hormone-releasing hormone, or GHRH, analog that is not FDA-approved for human use. It is designed to signal the pituitary gland to release growth hormone, which can then raise insulin-like growth factor 1, or IGF-1 [1][2][3].

Growth hormone and IGF-1 help regulate body composition, fluid balance, glucose metabolism, connective tissue, and growth signals in cells [5][6]. That same biology is why side effects matter: too much GH or IGF-1 activity can resemble acromegaly, a disease state of GH excess, with swelling, joint pain, carpal tunnel symptoms, and glucose problems [5].

CJC-1295 with DAC vs. CJC-1295 without DAC

CJC-1295 with DAC means CJC-1295 with Drug Affinity Complex, and it is not FDA-approved for human use [3]. DAC helps the peptide bind to albumin in blood, which extends how long it lasts; in one healthy-adult study, CJC-1295 with DAC had an estimated half-life of about 5.8 to 8.1 days [1].

CJC-1295 without DAC is often discussed as modified GRF 1-29, and it is also not FDA-approved for human use [3]. It is intended to be shorter acting, but published human safety data for non-DAC CJC-1295 is limited compared with FDA-approved endocrine drugs [3][4][8].

How it differs from HGH injections

Human growth hormone injections provide growth hormone directly. CJC-1295 is different because it aims to prompt the pituitary gland to release GH, which can raise IGF-1 downstream; it is not FDA-approved for this or any other human use [1][2][3].

Tesamorelin is useful context. Tesamorelin is an FDA-approved GHRH analog for reducing excess abdominal fat in adults with HIV and lipodystrophy, and its label warns about IGF-1 elevation, fluid retention, glucose intolerance, and malignancy-related precautions [8]. CJC-1295 does not have that FDA-approved indication [3][8].

What are the most common side effects of CJC-1295?

CJC-1295 side effects most often discussed include injection-site redness or irritation, flushing, headache, dizziness, water retention, tingling, nausea, and appetite changes. Because CJC-1295 is not FDA-approved and long-term human data are limited, the true rate of side effects in real-world use is not well defined [1][3][4].

Injection-site reactions

Injection-site reactions may include redness, itching, swelling, tenderness, or bruising. These effects can occur with injected peptides and biologic drugs, but CJC-1295 products used outside FDA-approved pathways may vary in sterility, purity, and strength, which can affect safety [3][9].

Flushing, headache, and dizziness

Flushing, headache, and dizziness have been reported with GHRH-related peptides and GH-axis stimulation [1][8]. If these symptoms are severe, sudden, or paired with chest pain, fainting, neurologic symptoms, or shortness of breath, urgent medical care is appropriate.

Water retention and tingling

Water retention can show up as puffiness, ankle swelling, tight rings, or weight change from fluid. Tingling or numbness may occur when fluid shifts irritate nerves, similar to carpal-tunnel-like symptoms seen in GH excess states [5][8].

Nausea and appetite changes

Some people report nausea or appetite changes with peptide injections, but CJC-1295-specific rates are not well established in large trials [1][3]. Persistent vomiting, dehydration, severe abdominal pain, or rapid swelling should be evaluated by a clinician.

What are the more serious risks of CJC-1295?

CJC-1295 may carry more serious risks because it can raise growth hormone and IGF-1 for days after exposure. In one study, participants received single subcutaneous injections of CJC-1295 with DAC at study-assigned doses ranging from 30 to 250 micrograms per kilogram; GH secretion increased for about 6 days while IGF-1 increased for about 9 to 11 days, and individual results varied [1].

Elevated IGF-1 and insulin resistance

IGF-1 is part of normal growth and repair signaling, but high or prolonged GH-axis activity can worsen insulin resistance in some people [5][6][8]. Tesamorelin’s FDA label includes warnings about glucose intolerance and recommends glucose monitoring in patients at risk [8].

Joint pain and swelling

Joint pain, muscle aches, swelling, and carpal-tunnel-like tingling are known concerns when GH or IGF-1 activity is too high [5][8]. These symptoms can be mild, but they can also affect sleep, grip strength, exercise, and daily movement.

Theoretical cancer-growth concerns

IGF-1 is involved in cell growth signaling, so clinicians are cautious in people with active malignancy, recent cancer, unexplained masses, or high cancer risk [7][8]. This does not mean CJC-1295 has been proven to cause cancer, but it does mean the risk cannot be dismissed, especially because long-term safety studies are limited [3][7].

Cardiovascular considerations

Fluid retention can affect blood pressure, edema, and heart symptoms in susceptible people [5][8]. People with heart failure, uncontrolled hypertension, untreated sleep apnea, or significant kidney disease should discuss GH-axis peptides with a physician before any use.

Does CJC-1295 affect testosterone or other hormones?

CJC-1295 mainly targets the growth hormone pathway, not the testosterone pathway. Its best-described hormonal effect is increasing GH and IGF-1; in the main healthy-adult study, CJC-1295 with DAC increased mean GH and IGF-1 after study-assigned injection, while CJC-1295 remained not FDA-approved for human use [1][3].

Other hormones still matter. GH, IGF-1, insulin, thyroid function, sleep, weight change, and sex hormones can interact in complex ways [5][6]. If a person has low testosterone symptoms, fertility goals, menstrual changes, thyroid disease, or pituitary disease, they need a broader hormone evaluation rather than assuming CJC-1295 is the right answer.

Are the side effects different with DAC vs. without DAC?

CJC-1295 with DAC lasts longer than versions described as CJC-1295 without DAC or modified GRF 1-29. The longer half-life, about 5.8 to 8.1 days in one study, may mean a longer window for GH and IGF-1-related effects such as fluid retention, tingling, joint pain, and glucose changes [1][5][8].

What are the long-term side effects of CJC-1295?

The honest answer is that long-term CJC-1295 safety in healthy adults is not well known. The best-known human study followed endocrine effects after limited exposure, not years of routine use, and FDA has flagged safety concerns for compounding [1][3].

Long-term concerns are based on GH and IGF-1 biology. Possible issues include persistent fluid retention, joint pain, carpal-tunnel-like symptoms, worsening insulin resistance, sleep apnea concerns, and acromegaly-like changes if GH-axis activity is excessive [5][6][8].

There is also uncertainty around cancer biology. Higher IGF-1 signaling has been associated with cancer risk in some epidemiologic research, but that evidence does not prove CJC-1295 causes cancer [7]. It does support caution in people with active cancer, recent cancer, or unexplained symptoms.

Who should avoid CJC-1295 or talk to a clinician first?

CJC-1295 should not be approached like a wellness supplement. People who are pregnant, breastfeeding, trying to conceive, under 18, or dealing with active malignancy should avoid it unless a physician with the right expertise evaluates the situation [3][8].

• People with active cancer, recent cancer, unexplained tumors, or high-risk cancer syndromes should seek physician evaluation because IGF-1 is involved in growth signaling [7][8].
• People with diabetes, prediabetes, insulin resistance, or a history of gestational diabetes need glucose and A1c review because GH-axis therapies can affect glucose metabolism [6][8].
• People with acromegaly, pituitary tumors, severe headaches, vision changes, or known endocrine disorders should not use GH-axis peptides without specialist care [5].
• People with heart failure, uncontrolled high blood pressure, kidney disease, edema, or untreated sleep apnea may be more vulnerable to fluid retention [5][8].
• People using anabolic steroids, testosterone therapy, thyroid medication, GLP-1 medications, or other peptides should review the full combination with a clinician because overlapping effects can be hard to predict [5][8].

What is the FDA status of CJC-1295, and why does it matter for safety?

CJC-1295 is not FDA-approved for any human use, and FDA has identified it as a bulk drug substance that raises significant safety concerns for 503A compounding [3]. This matters because FDA approval requires formal review of quality, safety, effectiveness, labeling, manufacturing, and post-market controls [9].

A 503A compounding pharmacy can prepare certain medications for individual patients when legal requirements are met, but compounded drugs are not FDA-approved in the same way as branded or generic drugs [9]. FDA’s concern list means extra caution is needed for CJC-1295 specifically, not just peptides as a category [3].

Some longevity peptides are currently under FDA review, with FDA materials from the April 15-16, 2026 reclassification process and PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026 [10]. That review process should not be read as approval, and it does not change CJC-1295’s current non-approved status [3][10].

How can side effects be reduced with medical supervision?

The safest first step is not a peptide protocol; it is a clinical review. A clinician can look for reasons CJC-1295 may be risky, including cancer history, pituitary disease, glucose problems, swelling, sleep apnea, or medications that affect hormones [5][8].

If a clinician is evaluating GH-axis therapy, baseline and follow-up labs may include IGF-1, fasting glucose, A1c, lipids, kidney function, liver tests, and other hormone labs when appropriate [5][8]. These checks do not remove all risk, but they can help catch excessive IGF-1, worsening glucose control, or other safety signals earlier.

People should also report swelling, numbness, joint pain, severe headache, vision changes, chest symptoms, shortness of breath, rapid fluid-related weight change, or new lumps promptly. Stopping or changing any peptide should be handled by a clinician, not by online advice.

For patients comparing regulated access options, Chia is one telehealth provider that offers clinician-reviewed care pathways for compounded GLP-1 medications and selected longevity peptides through licensed 503A pharmacy partners, when clinically appropriate and legally available.

What peptides stack well with CJC-1295?

CJC-1295 stacks are commonly discussed in clinical and research practice, but combination-specific trials are limited. CJC-1295, ipamorelin, and sermorelin are not FDA-approved for general wellness or longevity use, and combining peptides may increase overlapping side effects, especially GH and IGF-1-related swelling, tingling, joint pain, and glucose changes [3][4][5][8].

• CJC-1295 plus ipamorelin: This pairing is discussed because CJC-1295 acts through the GHRH pathway while ipamorelin acts through the ghrelin receptor to stimulate GH release. The safety caveat is that both can affect the GH/IGF-1 axis, so side effects and labs may overlap [4][5].
• CJC-1295 plus sermorelin: Both are GHRH-pathway peptides, so the mechanistic rationale is not additive in a simple way and may be redundant. The safety caveat is a higher risk of excessive GH-axis stimulation without good combination-specific evidence [4][5].
• CJC-1295 plus tesamorelin is generally not a casual wellness stack: tesamorelin is an FDA-approved drug for a specific HIV-lipodystrophy indication, and its label includes warnings about IGF-1 elevation, glucose intolerance, edema, and malignancy precautions. Combining GH-axis agents should only be considered by a qualified specialist, if at all [8].

Keep reading

Longevity Peptides

CJC-1295 Side Effects: What Patients Should Know Before Starting

Peptides

CJC Peptide (CJC-1295): What It Is, How It Works, and What the Evidence Shows

Longevity Peptides

CJC-1295 Peptide: How It Works, Benefits, Risks, and Legal Status